Proteomics

Dataset Information

0

Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma


ABSTRACT: The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being found only in a small subset of cases. Here, we performed integrated global quantitative tandem mass tag (TMT)-based proteomic and phosphoproteomic analyses and RNA sequencing in five paired pre-treatment and relapse samples from multiple myeloma patients to investigate non-genetic resistance mechanisms. These analyses revealed a CDK6-governed protein resistance signature that includes myeloma high-risk factors such as TRIP13 and RRM1. Overexpression of CDK6 in multiple myeloma cell lines reduced sensitivity to IMiDs while CDK6 inhibition by palbociclib or CDK6 degradation by proteolysis targeting chimeras (PROTACs) is highly synergistic with IMiDs in vitro and in vivo. In conclusion, we found upregulation of CDK6 to cause lenalidomide resistance in multiple myeloma that can be overcome by pharmacological intervention.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Cell, Cell Culture, Bone Marrow

DISEASE(S): Multiple Myeloma

SUBMITTER: Evelyn Ramberger  

LAB HEAD: Philipp Mertins

PROVIDER: PXD021265 | Pride | 2021-12-17

REPOSITORIES: Pride

Similar Datasets

2021-12-14 | GSE162403 | GEO
2012-05-01 | E-GEOD-33577 | biostudies-arrayexpress
2014-11-23 | E-GEOD-46053 | biostudies-arrayexpress
2020-02-21 | PXD012172 | Pride
2009-02-01 | E-GEOD-14519 | biostudies-arrayexpress
2010-03-23 | E-GEOD-20540 | biostudies-arrayexpress
2016-03-09 | E-GEOD-61693 | biostudies-arrayexpress
2008-06-17 | E-GEOD-9782 | biostudies-arrayexpress
2024-01-26 | PXD025808 | Pride
2021-06-15 | GSE171339 | GEO